New hope for kidney transplant patients: early rejection treatment trial launches
NCT ID NCT06291103
First seen Feb 23, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study looks at kidney transplant recipients who develop antibodies against their new kidney without any signs of kidney damage. Researchers want to see if switching to a drug called belatacept, along with standard treatments, can prevent further rejection better than staying on current medications. About 290 adults will take part, and the goal is to preserve kidney function and avoid graft loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.